Knee Arthroscopy for a Worn Meniscus: What the Sham Trials Revealed

When researchers compared knee arthroscopy for a worn, degenerative meniscus against a fake operation, the surgery worked no better than the placebo. In the Finnish FIDELITY trial, patients who received arthroscopic partial meniscectomy and patients who received a carefully staged sham procedure improved by nearly identical amounts a year later. Pooled analyses of individual patients across several trials reached the same conclusion. The design itself, placebo surgery, is the reason we can state this with confidence, and it offers a durable lesson in how to read surgical evidence.

What a degenerative meniscus tear is

The meniscus is a pad of fibrocartilage that cushions the knee. A degenerative tear is not the acute, twist-and-pop injury of a young athlete. It is the gradual fraying that shows up on MRI in middle-aged and older adults, often alongside early wear in the joint. These tears are extremely common, and here is the catch that makes them hard to study: many people who have one on imaging have no symptoms at all, and many people with knee pain and a tear on their scan are actually hurting from the surrounding osteoarthritis rather than the tear itself.

That overlap creates a trap for clinical reasoning. If a person has knee pain, an MRI shows a frayed meniscus, and the pain improves after an operation to trim it, the story feels complete. But two rival explanations fit the same facts. The trimming may have helped, or the person may have improved for reasons that had nothing to do with the surgery.

Why a placebo operation was needed

Most medical treatments are tested against a dummy pill. Surgery is harder, because the act of operating carries its own powerful effects. Undergoing a procedure, being cared for, resting and rehabilitating afterward, and expecting to get better all push symptoms in a favorable direction. Knee pain also waxes and wanes on its own, and people tend to seek treatment when symptoms peak, so improvement afterward is partly just regression toward the average. None of that requires the surgical step to have done anything.

To separate the effect of the meniscal trimming from everything that surrounds it, investigators built a sham-surgery design. Every patient went to the operating room, received anesthesia, and had the arthroscope inserted. For half of them, chosen at random, the surgeon then performed the partial meniscectomy. For the other half, the surgeon simulated the procedure, using the instruments and mimicking the sounds and sensations without removing meniscal tissue. Patients did not know which they had received, and the outcome assessors did not either. This is what "double-blind" means in a surgical context, and it is difficult to achieve, which is part of why the FIDELITY trial drew so much attention.

What the FIDELITY trial found

The trial, reported by Sihvonen and colleagues in the New England Journal of Medicine in 2013, enrolled 146 adults aged 35 to 65 who had symptoms of a degenerative medial meniscus tear and no osteoarthritis on imaging. Both groups improved substantially over the following year. On the two main symptom-and-function scores and on knee pain after exercise, the change from baseline to twelve months was statistically indistinguishable between the surgery group and the sham group. The authors concluded that in these patients the outcomes after arthroscopic partial meniscectomy were no better than after a sham procedure.

The follow-up matters as much as the headline. When the same cohort was examined five years later, reported in the British Journal of Sports Medicine in 2020, the two groups again showed comparable symptom relief, and the surgery group carried a slightly higher rate of radiographic osteoarthritis progression, with no offsetting benefit on patient-reported outcomes. A treatment that does not outperform placebo, and that may nudge the joint toward more visible wear, is a poor bargain.

What pooling the trials added

A single trial, however clean, invites the question of whether its result would hold elsewhere. A 2023 individual-participant-data meta-analysis in Osteoarthritis and Cartilage combined 605 randomized patients with MRI-confirmed degenerative meniscus tears across multiple trials, comparing arthroscopic partial meniscectomy against non-surgical or sham treatment. Working from individual patient records rather than published averages allows a more faithful pooled estimate. The finding held: pain, knee function, and quality of life improved to similar degrees regardless of which treatment patients received. The convergence of a rigorous sham trial and a broad pooled analysis is what turns a provocative single result into a settled reading of the evidence.

How to appraise a surgical claim

The meniscus story generalizes into a short checklist for weighing any operation.

Ask what the treatment is being compared against

"Patients got better after surgery" is not evidence that the surgery caused the improvement. The useful comparison is against the best alternative, and where feasible against a sham, so that the ceremony of the procedure is held constant on both sides.

Watch for the natural course of the condition

Conditions that fluctuate or tend to settle on their own will make almost any intervention look effective if there is no control group. Degenerative knee symptoms often ease over months regardless of what is done.

Separate the picture from the pain

An abnormality visible on a scan is not automatically the source of a symptom, especially when the finding is common in people without complaints. Treating the image rather than the person is a recurring error.

Give weight to blinding and follow-up

Blinded outcome assessment guards against wishful measurement, and longer follow-up catches harms and relapses that a short study would miss. FIDELITY is instructive precisely because it did both.

This is educational information about how evidence is evaluated, not medical advice; decisions about a specific knee belong in a conversation with a qualified clinician who knows the full picture.